Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.

about

Rituximab in the management of acute lymphoblastic leukemia.Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.

P2860

Q47196522-8E223CBB-A866-4647-BAB0-B4DF11EA6AB5 Q55205941-A1D0700B-C991-4152-90A6-96E116EAB108

P2860

Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.

Item

http://www.wikidata.org/entity/Q38646986

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.

@en

type

Item

label

Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.

@en

prefLabel

Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.

@en

P1476

Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.

@en

P2093

Caitlin R Rausch

http://www.w3.org/2001/XMLSchema#string

Elias J Jabbour

http://www.w3.org/2001/XMLSchema#string

Shilpa Paul

http://www.w3.org/2001/XMLSchema#string

P2860

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.

Liver Microvascular Injury and Thrombocytopenia of Antibody-Calicheamicin Conjugates in Cynomolgus Monkeys-Mechanism and Monitoring.

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.

P-glycoprotein Inhibition for Optimal Drug Delivery.

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.

P31

scholarly article

P356

10.2217/FON-2017-0233

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Hagop Kantarjian

P577

2017-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28776425

http://www.w3.org/2001/XMLSchema#string

Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.

about

P2860

P2860

Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698